CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2018—Integrated Diagnostics announced the e-publication of full results of a large prospective clinical trial validating its Xpresys Lung 2 in Chest, titled “Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (PulmonAry NOdule Plasma proTeomIc Classifier) trial”.
Read More »